Filing Flows › Evolent Health (EVH) › Q2 2026 › vs Q1 2026
Evolent Health (EVH) Q2 2026 vs Q1 2026 (quarter over quarter)
Evolent Health's revenue rose $156M (+31%) from $496M in Q1 2026 to $653M in Q2 2026.
Evolent Health, Q2 2026: revenue $653M (+47% year over year), operating margin -1.5%, net loss $28.4M, operating cash flow −$9.3M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $653M | $496M | $156M | +31% |
| Net loss | $28.4M | $26.6M | $1.7M | +7% |
| Costs & expenses | $681M | $523M | $158M | +30% |
| Operating costs | $662M | $507M | $155M | +31% |
| Interest & other, net | $16.1M | $15.1M | $965K | +6% |
| Income tax | $2.7M | $910K | $1.8M | +198% |
| Cost of revenue | $572M | $412M | $159M | +39% |
| SG&A | $68.8M | $72.8M | −$4.0M | -5% |
| Other operating costs | $21.6M | $21.6M | $11K | +0.1% |
| Operating cash sources | $46.1M | $33.2M | $12.9M | +39% |
| Depreciation & amortization | $21.6M | $21.6M | $11K | +0.1% |
| Share-based compensation | $15.2M | $10.6M | $4.6M | +43% |
| Cash used in operations | $9.3M | $984K | $8.3M | +846% |
| Net loss absorbed | $28.4M | $26.6M | $1.7M | +7% |
| Working capital & other | $17.7M | $6.6M | $11.2M | +170% |
Questions
How much did Evolent Health's revenue grow quarter over quarter in Q2 2026?
Evolent Health's revenue rose $156M (+31%) from $496M in Q1 2026 to $653M in Q2 2026.